Welcome to our dedicated page for AI / ML Innovations news (Ticker: AIMLF), a resource for investors and traders seeking the latest updates and insights on AI / ML Innovations stock.
AI/ML Innovations Inc. develops artificial intelligence and neural-network technology for digital health applications. The company’s platforms use signal processing and deep learning to convert biometric data into clinical insights, with recurring updates centered on ECG analysis, heart rate variability analytics, remote cardiac monitoring, and cardiovascular research support.
News for AIMLF also covers activity at its Neural Cloud Solutions subsidiary, including MaxYield™, CardioYield™, and Insight 360™ commercialization, reseller and distribution agreements, research-services collaborations, medical advisory board appointments, and capital-structure actions such as private placements, convertible debentures, warrants, options, and share issuances for debt settlement.
AIML (OTCQB:AIMLF) subsidiary NeuralCloud Solutions signed a non-binding commercial term sheet on December 9, 2025 with Culminate H Labs to integrate NeuralCloud's MaxYield™ ECG signal-processing and Insight360™ analytics into CH Labs' INTRINSICA DNA-guided biofeedback wellness platform.
The deal begins with a pilot to validate high-fidelity wearable ECG processing on smart ring devices, then intends to move toward structured commercialization with scalable per-device economics tied to CH Labs' distribution plans.
AIML (OTCQB:AIMLF) subsidiary NeuralCloud entered a pilot collaboration with Cornerstone Physiotherapy on December 2, 2025 to evaluate MaxYield™ signal‑processing and Insight360™ performance analytics for elite Hyrox athlete cardiac testing.
The pilot will deploy MaxYield for 1‑lead ECG denoising and automated labeling and use Insight360 to produce pilot‑level performance reports to help physiotherapists assess training responses, fatigue markers, and cardiac efficiency during high‑intensity functional fitness.
AIML (OTCQB:AIMLF) subsidiary NeuralCloud signed a non-binding commercial term sheet with Equimetrics on November 21, 2025 to integrate NeuralCloud's MaxYield™ AI signal‑enhancement engine and CardioYield™ visualization layer into Equimetrics' V-PRO Clinical Monitoring and S-PRO Sports Performance product lines.
The integration will supply API access to denoised, labeled ECG waveforms with beat-by-beat PQRST intervals and structured summaries to support faster throughput, reduced manual review, and improved diagnostic confidence for equine clinicians and performance specialists.
Neural Cloud (OTCQB:AIMLF) announced a pilot with The Hospital for Sick Children (SickKids) beginning November 24, 2025 to evaluate its MaxYield™ AI platform in pediatric cardiac care. The project will test AI-driven ECG signal cleaning, beat-by-beat interval analysis, and multimodal models that combine ECG waveforms with clinical and textual data to predict cardiac deterioration in pediatric inpatients. The pilot is led by Dr. Cedric Manlhiot and will assess real-world performance, reliability, safety validation, drift monitoring, and fairness for potential future regulated medical uses.
AI/ML Innovations (AIMLF) announced a U.S. patent allowance (U.S. Patent No. 12,465,266) on November 11, 2025, covering its core machine‑learning architecture for ECG denoising, beat‑level wave morphology identification, and mapping patterns to cardiac rhythm conditions.
The allowance is the first granted patent in AIML's IP portfolio, is claimed broadly without substantive narrowing for prior art, and is said to support the company's MaxYield™ and CardioYield™ products as AIML advances clinical validation, regulatory pathways, and commercial deployment.
AI/ML Innovations (OTCQB:AIMLF) subsidiary NeuralCloud Solutions has engaged Kingston-based Lonacas Consultants to lead a regulatory submission for its CardioYield™ AI ECG interpretation software paired with a single-lead wearable chest strap to the Jamaica Ministry of Health & Wellness - Standards and Regulation Division on November 4, 2025.
The collaboration targets local registration, regulatory validation, and scalable deployment across clinics, hospitals, and community health centers to improve access to Holter-grade cardiac diagnostics in Jamaica’s tropical climate. AIML also granted 1,405,000 stock options at an exercise price of $0.10, effective November 4, 2025, expiring five years from the grant date with staged vesting.
AI/ML Innovations (OTCQB:AIMLF) subsidiary NeuralCloud Solutions is launching a multi-stage pilot of its CardioYield AI ECG reporting platform with a multi-location Canadian cardiology clinic on October 21, 2025.
The pilot will use the MaxYield signal-enhancement neural network to provide automated Holter ECG denoising, labeling, and structured report generation. The Clinic Partner performs >1,000 Holter assessments per month, enabling benchmarking of AI-driven workflows. Pilot phases: internal validation, in-clinic pilot, then full integration. Any commercialization is conditional on Health Canada Class II clearance. The Clinic Partner's identity remains confidential pending mutual consent.
AIML (OTCQB:AIMLF) announced on October 15, 2025 that its subsidiary NeuralCloud Solutions is launching a pilot of CardioYield with Heartdent Center in Kingston, Jamaica.
The feasibility study will pair a single-lead ECG wearable chest strap with CardioYield's AI Holter-reporting and ECG analysis to test workflow integration, operational impact, and a low-cost, scalable diagnostic model aimed at expanding access to cardiac care in Jamaica.
The pilot seeks to validate clinical workflow, improve affordability and reduce wait times for diagnostics in a country where cardiovascular disease accounts for about one-third of deaths.
AI/ML Innovations (CSE:AIML / OTCQB:AIMLF) announced that its subsidiary NeuralCloud Solutions is launching a pilot with the Toronto Heart Centre to evaluate CardioYield™, the company's AI visualization and reporting interface powered by MaxYield™. The study will compare Holter ECG reporting workflows, measuring technician efficiency, report turnaround time, and analysis quality versus current industry-standard software.
The release describes CardioYield™ features including automated removal of baseline wander and motion artifacts, beat-level PQRST labeling with interval calculations, and a unified reporting interface intended to reduce repetitive corrections and analyst fatigue. Management and clinical leaders framed the pilot as a step to quantify efficiency and diagnostic reliability in real-world practice.
AI/ML Innovations (OTCQB:AIMLF) has announced a strategic pilot project between its subsidiary Neural Cloud Solutions and the BC Brain Wellness Program (BCBWP). The collaboration will utilize Neural Cloud's MaxYield ECG technology to study the heart-brain connection in patients with neurological conditions.
The pilot represents the first deployment of MaxYield, an AI-driven ECG signal-enhancement engine, in a neurology-focused exercise program. The technology will analyze physiological data from individuals with conditions like Parkinson's disease, stroke, and multiple sclerosis during supervised exercise settings to understand how cardiac responses may correlate with neurological status and outcomes.
This initiative aims to verify the algorithm's performance in real-world settings and establish groundwork for future research collaborations, focusing on condition-specific cardiac responses and potential HR/HRV biomarkers.